Semustine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100765

CAS#: 13909-09-6

Description: Semustine is a drug used in chemotherapy. It is structurally similar to lomustine, being distinguished from it only by an additional methyl group. It has been taken off the drug market for investigation of its cancerous effects, rated as IARC Group 1 carcinogen or a known carcinogen.


Chemical Structure

img
Semustine
CAS# 13909-09-6

Theoretical Analysis

MedKoo Cat#: 100765
Name: Semustine
CAS#: 13909-09-6
Chemical Formula: C10H18ClN3O2
Exact Mass: 247.10875
Molecular Weight: 247.72
Elemental Analysis: C, 48.48; H, 7.32; Cl, 14.31; N, 16.96; O, 12.92

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-03-05. Prices are subject to change without notice.

Semustine is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Synonym: CCNU methyl, MCCNU, methyl CCNU, methylCCNU, MeCCNU

IUPAC/Chemical Name: N-(2-Chloroethyl)-N'-(4-methylcyclohexyl)-N-nitrosourea

InChi Key: FVLVBPDQNARYJU-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H18ClN3O2/c1-8-2-4-9(5-3-8)12-10(15)14(13-16)7-6-11/h8-9H,2-7H2,1H3,(H,12,15)

SMILES Code: O=C(NC1CCC(C)CC1)N(CCCl)N=O

Appearance:
White to light yellow crystalline power

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Certificate of Analysis:

Safety Data Sheet (SDS):

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 247.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Kobiakov GL. [Clinical significance of mustoforan in management of malignant glioma]. Vopr Onkol. 2007;53(6):724-9. Review. Russian. PubMed PMID: 18416147.

2: Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. Review. PubMed PMID: 11219485.

3: Kodaira S, Shatari T, Nozawa K. [Recent advances is surgical adjuvant chemotherapy for colorectal cancer]. Gan To Kagaku Ryoho. 2000 Dec;27(14):2201-8. Review. Japanese. PubMed PMID: 11142163.

4: Saka M, Sasako M, Katai H, Sano T. [Current status and problem of adjuvant chemotherapy for curatively resected gastric cancer]. Gan To Kagaku Ryoho. 2000 Nov;27(13):2033-42. Review. Japanese. PubMed PMID: 11103234.

5: Hay JM, Msika S. [Radiotherapy and chemotherapy in the treatment of cancer of the rectum]. J Chir (Paris). 2000 Feb;137(1):13-5. Review. French. PubMed PMID: 10790613.

6: Tsukagoshi S. [Fundamental studies on the surgical adjuvant chemotherapy to support the clinical efficacies]. Gan To Kagaku Ryoho. 1997 Aug;24(10):1213-20. Review. Japanese. PubMed PMID: 9279339.

7: Cachat F, Guignard JP. [The kidney in children under chemotherapy]. Rev Med Suisse Romande. 1996 Dec;116(12):985-93. Review. French. PubMed PMID: 9026889.

8: [Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994]. Ann Gastroenterol Hepatol (Paris). 1995 Sep;31(4):226-30, 233-6. Review. French. PubMed PMID: 7486820.

9: Shparik IaV. [Adjuvant chemotherapy of gastric cancer]. Klin Khir. 1995;(5):38-41. Review. Ukrainian. PubMed PMID: 8646632.

10: Mezger J. [Adjuvant therapy in colorectal carcinomas]. Dtsch Med Wochenschr. 1994 Dec 2;119(48):1663-8. Review. German. PubMed PMID: 7988367.



Additional Information

semustine is a  methylated derivative of carmustine with antineoplastic activity. As an alkylating agent, semustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)